HealthQuill bladder cancer
Johnson & Johnson’s investigational treatment to help people with a specific type of early-stage bladder cancer has shown 80% of the patients to be free of cancer for up to nine months, and 94% were able to avoid surgical removal of the organ after a year of follow-up.
Drugs Health Pharma

J&J’s trial drug for a type of bladder cancer helps avoid organ removal 

HQ Team April 27, 2025: Johnson & Johnson’s investigational treatment to help people with a specific type of early-stage bladder cancer has shown.

Read More
FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical trials showed “significant” improvement in overall survival rates.
Drugs Pharma Research

Pfizer’s experimental drug improves survival rates in hard-to-treat bladder cancer

Bharti Jayshankar January 11, 2024: In a breakthrough for bladder cancer treatment, Pfizer’s experimental anti-PD-1 therapy demonstrated superior efficacy compared to the current.

Read More
Pizer Inc.’s late-stage trial of an antibody treatment for a certain type of bladder cancer has shown significant improvement in time patients remained free of complications, according to a company statement.
Drugs Health Medical

Pfizer’s trial antibody for type of bladder cancer meets main goal

Pizer Inc.’s late-stage trial of an antibody treatment for a certain type of bladder cancer has shown significant improvement in time patients remained.

Read More
Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to extend the lives of patients who had undergone prior treatments.
Drugs Health Pharma

Gilead’s end-stage confirmatory trials of bladder cancer drug fail

Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.

Read More
Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results
Drugs Health Medical

J&J stops trials on drug to treat muscle-invasive bladder cancer

Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results

Read More
Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in 27 member states and other nations.
Drugs Health Pharma

EC approves Merck’s bladder cancer combination therapy in adults 

Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in.

Read More
Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the USFDA has given the green light to the company’s Anktiva treatment.
Drugs Health Pharma

USFDA grants approval for ImmunityBio’s bladder cancer drug

HQ Team April 23, 2024: Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the.

Read More
FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical trials showed “significant” improvement in overall survival rates.
Drugs Health Pharma

J&J’s metastatic bladder cancer drug gets full FDA approval

HQ Team January 21, 2024: The FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical.

Read More
Roche’s atezolizumab drug Tecentriq, to treat cancer, was approved by Britain’s Medicines and Healthcare Products Regulatory Agency.
Drugs Health Pharma

Roche’s under-the-skin cancer injection gets Britain’s nod 

HQ Team August 30, 2023: Roche’s atezolizumab drug Tecentriq, to treat cancer, was approved by Britain’s Medicines and Healthcare Products Regulatory Agency. Tecentriq.

Read More
gene therapy
Drugs Medical

FDA approves gene therapy for treatment of high-risk bladder cancer

The FDA approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy for the treatment of high-risk bladder cancer.

Read More